OncoMatch/Clinical Trials/NCT06214572
Radiation Therapy in Unresectable Gall Bladder Cancer
Is NCT06214572 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Systemic therapy (Gemcitabine plus Cisplatin) and Systemic therapy (Gemcitabine plus oxaliplatin) for gall bladder cancer.
Treatment: Systemic therapy (Gemcitabine plus Cisplatin) · Systemic therapy (Gemcitabine plus oxaliplatin) · Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab) · Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel) — The goal of this clinical trial is to compare two treatment regimes, namely, systemic therapy (chemotherapy and/or immunotherapy) alone vs. systemic therapy and radiation therapy in patients with inoperable but localized gallbladder cancer. The main questions it aims to answer are: * Whether adding radiation therapy to systemic therapy improves overall survival? * What are the effects on other endpoints like cancer-free intervals, side effects, and quality of life? Participants will be randomly assigned to one of the two treatment regimes mentioned earlier by a computer-based program. Researchers will compare survival and quality of life outcomes between the two groups.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: gemcitabine-based chemotherapy — initial
Cannot have received: abdominal therapeutic radiation
Lab requirements
Blood counts
Hb > 80 g/L, ANC ≥ 1.5 x 10^9/L, platelets ≥ 100 x 10^9/L
Kidney function
Creatinine ≤ 1.5 ULN, Creatinine clearance >= 50 mL/min
Liver function
bilirubin ≤ 2 x upper limit normal (ULN), AST/ALT ≤ 5 x ULN, alkaline phosphatase ≤ 6 x upper limit normal (ULN), S. albumin ≥ 30 g/L
Normal hematological and renal and hepatic functions allowing safe delivery of chemotherapy Hematological- Hb> 80 g/L, ANC ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L. Liver functions- bilirubin ≤ 2 x upper limit normal (ULN), AST/ALT ≤ 5 x ULN, alkaline phosphatase ≤ 6 x upper limit normal (ULN) S. albumin ≥ 30 g/L Renal function- Creatinine ≤ 1.5 ULN, Creatinine clearance >= 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify